A Phase 1 interventional study of Amodiaquine (Test) and Amodiaquine (Comparator) in Falciparum Malaria, sponsored by Pfizer. Completed at 1 site in Singapore. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-04-21.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
The study will determine if amodiaquine tablet (Pfizer), an antimalaria agent, is pharmaceutically equivalent to a comparator product (Arsuamoon-Guilin China).
384 studies on the registry are indexed under Malaria, Falciparum; 38 are open to participants now.
This study's enrollment of 38 is below the median of 132 across 319 interventional studies indexed under Malaria, Falciparum.
Browse Malaria, Falciparum studies →Pfizer is the lead sponsor of 3,244 studies on the registry; 139 are open to participants now.
Of its 582 completed or terminated interventional studies of FDA-regulated products, 381 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Amodiaquine (Test)
Drug: Amodiaquine (Comparator)
Oral tablet, single dose, 1 X 300 MG
Also known as: Camoquin
Oral tablet, single dose, 2 X 150 MG
Also known as: Camoquin
AUC and Cmax of amodiaquine
Time frame: 1 month
Tolerability
Time frame: 1 month
This study is completed, as verified in Apr 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pfizer